Navigation Links
1.0mm Trephine with Handle

Products1.0mm Trephine with Handle
Company Medtronic Xomed, Inc.
Item 1.0mm Trephine with Handle
Features 
Description Reusable, stainless steel trephine with handle.
Info Medtronic Xomed, Inc.
Customer Service: (800) 874-5797
Web site: http://www.xomed.com/

Related medicine products :

1. Retinal Forceps: Smooth 1.0mm Tips, Vertical Action
2. 11.0mm Open Trephine Handle
3. 11.0mm Trephine Handle
4. Troutman Punch Piston, 9.0 -11.0mm
5. Castroviejo Corneal Trephine Set
6. Universal Trephine Handle with Cottingham Punch
7. Storz Universal Trephine Handle
8. Michele Vertebral Biopsy Trephine
9. Galt Skull Trephine
10. Disposable Trephine Blade (set of 5)
11. 7.25mm Open Trephine Handle
A sophisticated research tool that allows to see the fundus picture of the area which is being stimulated. Besides it also includes the refractive pupil camera enabling the examiner to switch between
5 mm
Cannula and irrigation extension. Overall Length 150 mm (6.25"). Light Curve.
Produce clean 0.75 mm round hole without tissue tags. Serrated squeeze action handle.
Medicine Products:
(Date:7/18/2008)...est weight loss yields significant health benefits...oalition -- a group of,experts on overweight and o...dia to reevaluate the way they report on weight lo...ed news coverage and editorial content that,leads ... dieters if they,lose an enormous amount of weight...
(Date:7/18/2008)...n Is Not What America Signed Up For, WASHINGTON, ... McCain,s,top economic advisor, Phil Gramm, echoed...s were "psychological" by saying Americans are in ... "nation of whiners." While McCain,distanced himse...ard as,McCain,s top economic adviser. Now, John Mc...
(Date:7/18/2008)... Behavior spanning the wide spectrum of the animal...rnational Behavioral Ecology Congress, hosted by t...n Aug. 10 -14, 2008, at Cornell University in Itha...e congress will feature plenary sessions on: , ...olutionary biology, Yale University, on "When Theo...
(Date:7/18/2008)...ren preventive antibiotics within one hour before ...sk for serious infections after the surgery, sugge...ugust issue of Pediatric Infectious Disease Journ...en who received antibiotics outside of the golden ...ely to develop serious infections at the surgery s...
Breaking Medicine News(10 mins):Health News:Medical Experts Call on Media to Rethink Coverage of Weight Loss 2Health News:Medical Experts Call on Media to Rethink Coverage of Weight Loss 3Health News:DNC: McCain Watch: The Economy 2Health News:DNC: McCain Watch: The Economy 3Health News:Averting postsurgical infections in kids: Give antibiotics within hour before first incision 2
...y probably be small if the trip isn't to Asia. Pub...ntly known about the virus. However people can be ...strong filters against viruses. There have even be...s as possible. Newer flights are equipped with sop...
...ritish Medical Association (BMA) is advising peopl...isks. While the government does not recommend the ...their use. A report from WHO calls for an urgent n... of increased ultra-violet exposure. A tan, even w...
...e lifestyle with limiting TV time could prevent ob...n the US TV watching results in a lower metabolic ...ing board games, reading, writing or driving a car... in children. The health campaigns are focussed on...
...an detrimental effect on infant's brain, reducing ...med, it a reason behind increasing language learni...societies, the hearing center of a baby's sensitiv...iment conducted on young rats, the hearing center,...
Other Medicine News:
(Date:7/17/2008)...bon Improved the Clinical Course of Alzheimer,s Di...cant Improvements in Memory and Thinking, Act...tion -, SAN FRANCISCO, July 17 /PRNewswire-FirstC...nounced publication of the results of its first,Al...vestigational drug,Dimebon in the July 19, 2008 is...
(Date:7/17/2008)...SING-WEIHENSTEPHAN and JENA, Germany, July 17 /PRN...y developing Anticalins(R), a novel,class of targe... GmbH, a,full-service contract manufacturer of bio... milestone in the development of Pieris, PRS-050,A...loped PRS-050 as a next generation VEGF antagonist...
(Date:7/17/2008)...aily TMC278, the third anti-HIV compound to be dev...y portfolio -, YARDLEY, Pa., July 17 /PRNewswire/...hat two major phase III efficacy trials examining ... transcriptase inhibitor (NNRTI),in treatment-nai... The,global trials will compare the efficacy, safe...
(Date:7/17/2008)...S data from Neuradiab(TM) compares favorably to da...O, July 17 / Bradmer Pharma...pany dedicated to the development and,commercializ...ion free,survival (PFS) data from two previously c...lastoma multiforme (GBM) patients. As an explorato...
Breaking Medicine Technology:Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimer's Disease 2Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimer's Disease 3Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimer's Disease 4Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimer's Disease 5Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050 2Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV 2Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV 3Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials 2Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials 3Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials 4Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials 5Nastech to Establish Subsidiary MDRNA Inc as an Independent Company to Focus on the Development of RNA Based Therapeutics 6265 1Nastech to Establish Subsidiary MDRNA Inc as an Independent Company to Focus on the Development of RNA Based Therapeutics 6265 2Nastech to Establish Subsidiary MDRNA Inc as an Independent Company to Focus on the Development of RNA Based Therapeutics 6265 3Nastech to Establish Subsidiary MDRNA Inc as an Independent Company to Focus on the Development of RNA Based Therapeutics 6265 4Neuralstem Inc Reports 2007 Third Quarter Financial Results and Events 6262 1Neuralstem Inc Reports 2007 Third Quarter Financial Results and Events 6262 2Neuralstem Inc Reports 2007 Third Quarter Financial Results and Events 6262 3Neuralstem Inc Reports 2007 Third Quarter Financial Results and Events 6262 4Neuralstem Inc Reports 2007 Third Quarter Financial Results and Events 6262 5Neuralstem Inc Reports 2007 Third Quarter Financial Results and Events 6262 6Neuralstem Inc Reports 2007 Third Quarter Financial Results and Events 6262 7Sound medicine at Acoustics Meeting 6259 1Sound medicine at Acoustics Meeting 6259 2Sound medicine at Acoustics Meeting 6259 3Sound medicine at Acoustics Meeting 6259 4Sound medicine at Acoustics Meeting 6259 5Sound medicine at Acoustics Meeting 6259 6Sound medicine at Acoustics Meeting 6259 7Sound medicine at Acoustics Meeting 6259 8Babies Born Few Weeks Early Face Higher Death Risk 6256 1Babies Born Few Weeks Early Face Higher Death Risk 6256 2
...ined Improvements in Blood Glucose,Control and Pro...Newswire-FirstCall/ -- Amylin,Pharmaceuticals, Inc...s from a study that showed BYETTA(R) (exenatide) i...els and progressive weight,loss through three and ... associated with improvements in cardiovascular ri...
...INESS WIRE)--June 25, 2007--Gilead,Sciences, Inc. ...ase III clinical trial evaluating the company,s on...oxil fumarate or tenofovir,DF) 300 mg as a potenti...nfection, met its primary efficacy endpoint. The d...y,s once-daily antiviral,drug Hepsera(R) (adefovir...
Other Medicine Technology:Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 2Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 4Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 5Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 6Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6